Navigation Links
Watson Promotes Robert Stewart to Executive Vice President, Global Operations
Date:8/3/2010

MORRISTOWN, N.J., Aug. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI) today announced that Robert Stewart, who joined the Company in November 2009 as Senior Vice President, Global Operations, has been promoted to Executive Vice President, Global Operations. Mr. Stewart will continue to report to Paul Bisaro, President and Chief Executive Officer of Watson.

Mr. Stewart will assume responsibility for managing Global Generic Research and Development activities, in addition to having responsibility for Global Operations (manufacturing, supply chain, engineering, facilities and EH&S), Global Quality and Regulatory and Global Information Technology.

"This promotion recognizes the contributions Bob and his team have made in integrating the assets, technologies and resources acquired from Arrow and in continuing to maximize the potential of our global supply chain," said Bisaro.  "As a result of this promotion, the three significant components of our business -- Global Generics, Global Brands and Global Operations -- will now be led by Executive Vice Presidents, reporting directly to me.  In addition, moving Generic R&D under Global Operations recognizes that close coordination between R&D and Operations is critical to accelerating speed to market.  Bob will now assume responsibility for ensuring that the process from product development to approval and distribution is seamless and efficient, enhancing our ability to compete in the markets we serve with products that create increased value for our customers and our shareholders."

Mr. Stewart joined Watson following an eight-year career at Abbott Laboratories, where he most recently served as Divisional Vice President, Global Supply Chain.  From 2005 until 2008, he served as Divisional Vice President, Quality Assurance.  Prior to this position, Mr. Stewart was Abbott's Divisional Vice President for U.S./Puerto Rico and Latin America Plant Operations, as well as Director of Operations for Abbott's Whippany, NJ plant.  Prior to Abbott, he worked for Knoll Pharmaceutical Company and Hoffman La-Roche Inc.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on urology and women's health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others,  such risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended March 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms Renvela® for Oral Suspension Patent Challenge
2. Watson to Host Conference Call and Webcast to Discuss Second Quarter 2010 Earnings
3. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
4. Watsons Generic Prograf® 5 mg Receives FDA Approval
5. Watson Launches Generic Exelon®
6. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
7. Watson to Present at the Wells Fargo Securities 2010 Healthcare Conference
8. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
9. Watsons Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval
10. Watson Launches Generic Version of LIPITOR® in Canada
11. Watson to Present at the 2010 Citi Investment Research Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/13/2017)... Sept. 13, 2017   OrthoAtlanta has been named ... Football Host Committee (AFHC) for the 2018 College Football Playoff ... 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... AFHC "I,m In" campaign, participating in many activities leading up ... ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):